Modeling cost-effectiveness analysis of treatment sequencing

Abstract

In clinical practice, patients with cancer often undergo treatment with a sequence of drugs, usually because of diminishing effectiveness over time or resistance development. However, few cost-effectiveness analyses have included that fact in their model. This paper aims at closing that gap by presenting a model that reflects the possibility of the patient switching from one therapeutic agent to another one throughout the long-term duration of his/her life.